Tenderwize
Retour à la recherche

Open-house rebate agreement for Omalizumab

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 33 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Omalizumab (ATC-Code nach WHO: R03DX05)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice says participation documents must be obtained from the DTVP project space after access approval, and further...

Only pharmaceutical undertakings under § 4(18) AMG for the offered product may participate; local representatives quali...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive pharmaceutical rebate agreement for medicines containing Omalizumab.
  • Open-house participation model with no individual negotiations.
Afficher le résumé complet

Open-house supply arrangement for the active substance Omalizumab (ATC R03DX05) with AOK PLUS. It is a non-exclusive pharmaceutical rebate agreement under § 130a(8) SGB V, open to all interested pharmaceutical companies that meet the stated participation conditions. No individual negotiations or delivery exclusivity apply. The notice states that quantities are unknown and minimum purchase volumes are not guaranteed. Participation documents are available via DTVP project space, but the extracted procurement documents were not provided for analysis.

Risques

The notice says participation documents must be obtained from the DTVP project space after access approval, and further...

Only pharmaceutical undertakings under § 4(18) AMG for the offered product may participate; local representatives quali...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • Required documents explicitly mentioned: completed declaration of no exclusion grounds and declaration regarding Russia sanctions.

Administrative

  • Participation documents must be obtained via the DTVP project space after access approval.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Omalizumab

Non-exclusive supply arrangement for pharmaceutical products containing Omalizumab (ATC R03DX05). The lot is an open-house model, so any eligible pharmaceutical company may join during the participation period. No exclusivity, no guaranteed minimum quantities, and no individual contract negotiations are stated. Performance location is Dresden, Germany, with coverage indicated for Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Sep 2025 - Sep 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 30, 2026

Détails de la procédure

Date de publication
24 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
552774-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30